{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=LANTUS%C2%AE+SOLOSTAR%C2%AE+INSULIN+PEN", "query": { "intervention": "LANTUS® SOLOSTAR® INSULIN PEN" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 14, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=LANTUS%C2%AE+SOLOSTAR%C2%AE+INSULIN+PEN&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-07T16:36:17.139Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01226043", "title": "Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Insulin Glargine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 405, "start_date": "2010-10", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2013-08-12", "last_synced_at": "2026-10-07T16:36:17.139Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01226043" }, { "nct_id": "NCT01768559", "title": "Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Lixisenatide (AVE0010)", "type": "DRUG" }, { "name": "Insulin glulisine QD", "type": "DRUG" }, { "name": "Insulin glulisine TID", "type": "DRUG" }, { "name": "Insulin Glargine (Mandatory background drug)", "type": "DRUG" }, { "name": "Metformin (Background drug)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 894, "start_date": "2013-01", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2017-01-04", "last_synced_at": "2026-10-07T16:36:17.139Z", "location_count": 46, "location_summary": "Sun City, Arizona • Tempe, Arizona • Little Rock, Arkansas + 41 more", "locations": [ { "city": "Sun City", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Mesa", "state": "California" }, { "city": "Mission Viejo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01768559" }, { "nct_id": "NCT03668808", "title": "Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "Insulin Degludec", "type": "DRUG" }, { "name": "Insulin Glargine", "type": "DRUG" }, { "name": "TRESIBA® FLEXTOUCH®", "type": "DEVICE" }, { "name": "LANTUS® SOLOSTAR® INSULIN PEN", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sansum Diabetes Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 25, "start_date": "2018-11-16", "completion_date": "2020-09-19", "has_results": true, "last_update_posted_date": "2022-11-01", "last_synced_at": "2026-10-07T16:36:17.139Z", "location_count": 2, "location_summary": "Santa Barbara, California • Honolulu, Hawaii", "locations": [ { "city": "Santa Barbara", "state": "California" }, { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT03668808" }, { "nct_id": "NCT01117350", "title": "Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Insulin glargine", "type": "DRUG" }, { "name": "Liraglutide", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "35 Years to 75 Years" }, "enrollment_count": 978, "start_date": "2010-07", "completion_date": "2013-03", "has_results": true, "last_update_posted_date": "2014-04-11", "last_synced_at": "2026-10-07T16:36:17.139Z", "location_count": 45, "location_summary": "Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 39 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "La Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01117350" }, { "nct_id": "NCT00975286", "title": "24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Lixisenatide (AVE0010)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Insulin glargine", "type": "DRUG" }, { "name": "Pen auto-injector", "type": "DEVICE" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Thiazolidinedione (TZD)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 446, "start_date": "2009-10", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2016-10-11", "last_synced_at": "2026-10-07T16:36:17.139Z", "location_count": 23, "location_summary": "Mesa, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 19 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Mountain Home", "state": "Arkansas" }, { "city": "Concord", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00975286" }, { "nct_id": "NCT03371108", "title": "Gan & Lee Insulin Glargine Target Type (2) Evaluating Research", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Gan & Lee Insulin Glargine Injection", "type": "BIOLOGICAL" }, { "name": "Lantus®", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Gan and Lee Pharmaceuticals, USA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 567, "start_date": "2017-10-31", "completion_date": "2019-04-17", "has_results": true, "last_update_posted_date": "2022-04-01", "last_synced_at": "2026-10-07T16:36:17.139Z", "location_count": 57, "location_summary": "Birmingham, Alabama • Tuscumbia, Alabama • Phoenix, Arizona + 45 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Tuscumbia", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03371108" }, { "nct_id": "NCT02058147", "title": "Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Insulin glargine/lixisenatide Fixed Ratio Combination", "type": "DRUG" }, { "name": "Insulin glargine (HOE901)", "type": "DRUG" }, { "name": "Lixisenatide (AVE0010)", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1170, "start_date": "2014-02", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2017-05-09", "last_synced_at": "2026-10-07T16:36:17.139Z", "location_count": 118, "location_summary": "Phoenix, Arizona • Tempe, Arizona • Little Rock, Arkansas + 98 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02058147" }, { "nct_id": "NCT01240200", "title": "Satisfaction of Treatment Among Elderly Patients With Insulin Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus" ], "interventions": [ { "name": "Glargine", "type": "DRUG" }, { "name": "glargine via insulin pen", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 49, "start_date": "2011-01", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2018-10-31", "last_synced_at": "2026-10-07T16:36:17.139Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01240200" }, { "nct_id": "NCT01476475", "title": "Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Insulin glargine /lixisenatide Fixed Ratio Combination", "type": "DRUG" }, { "name": "Insulin glargine", "type": "DRUG" }, { "name": "Metformin (Background drug)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 323, "start_date": "2011-11", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2017-02-10", "last_synced_at": "2026-10-07T16:36:17.139Z", "location_count": 14, "location_summary": "Little Rock, Arkansas • Paramount, California • Larenceville, Georgia + 11 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Paramount", "state": "California" }, { "city": "Larenceville", "state": "Georgia" }, { "city": "Roswell", "state": "Georgia" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01476475" }, { "nct_id": "NCT03371082", "title": "Gan & Lee Insulin Glargine Target Type (1) Evaluating Research", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "Gan & Lee Insulin Glargine Injection", "type": "BIOLOGICAL" }, { "name": "Lantus®", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Gan and Lee Pharmaceuticals, USA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 576, "start_date": "2017-10-31", "completion_date": "2019-08-19", "has_results": true, "last_update_posted_date": "2024-05-14", "last_synced_at": "2026-10-07T16:36:17.139Z", "location_count": 50, "location_summary": "Birmingham, Alabama • Fresno, California • Newport Beach, California + 41 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fresno", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "Tarzana", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03371082" } ] }